Gene therapies face commercial headwinds in non-fatal disease settings where there are reasonable standards of care.

— Racquel Bracken

Biotech performance will be more mixed in H1 '24 than the end of 2023 due to overly optimistic street expectations and M&A will remain strong.

— Ken Greenberg

Small-molecule drugs will start to become popular again, but simple antibody formats will remain depressed by payload-based approaches (ADCs, targeted radionuclides, etc.).

— Mariana Mihalusova

Dive In With

Sami Inkinen

CEO & Founder, Virta Health

Tell us something you're really proud of in 2023?

In 2023 we doubled our total gross profit YoY while keeping our other costs flat. This was powerful proof that our product and business model can deliver strong operating leverage in practice, not just on a spreadsheet. I’m also proud that our team was able to rapidly capitalize on and respond to the “GLP-1/Ozempic wave” to better serve our clients and patients.

What is something you cannot live without?

My breath, my bicycle. In that order.

What do you hope to improve in 2024?

As a company focused on treating T2 diabetes and obesity, our biggest 2024 opportunity and also scaling challenge is to help our Plan, employer and PBM clients address the complexities (and rapidly increasing costs) of the GLP-1 drugs. Another area of big investment is to accelerate our AI investments to continue to improve patient experience and scalability.

Best lesson learned last year?

A downturn, high cost of capital and incredibly cost-conscious customers are fantastic for business when you can sell and deliver real substance and not just sizzle.

Relentless Execution

Patrick Conway  |  CEO of Optum Rx with Bryan Roberts & Bob Kocher

C.O.R.E Culture with the Right Team

Michael Henderson  |  CEO of Apogee Therapeutics with Andrew Gottesdiener & Nimish Shah

Take the Road Less Traveled

Dr. Sheila Gujrathi  |  Biotech Industry Veteran with Nimish Shah

Dive In With

Heather Turner

CEO, Carmot Therapeutics

Biggest lesson learned last year?

Being prepared for anything was an important aspect of 2023. I am grateful we didn't prematurely eliminate a strategic option and put ourselves in a position to take advantage of the space that we were in and the market opportunities.

What surprised you about 2023?

The speed in which our specific landscape shifted. At one point we were targeting an IPO in early 2024 and then a month later we were targeting an IPO a.s.a.p. in 2023.

What challenge had the biggest impact on Carmot last year?

Having a lean team was quite a challenge, but we were a highly functional team that worked very well together. Every single person on the team stepped up and did so much more than they were hired to do.

Advice for biotech entrepreneurs?

Don't allow the doubts of others to impact the belief you have in yourself. It is absolutely true that others won't believe in you if you don't believe in yourself.

Molly He

Element Biosciences

Element Biosciences' CEO and co-founder, Molly He, was recognized on Forbes' "50 over 50" list.

Noah Lang

Stride

Stride's CEO and co-founder, Noah Lang, was included in Business Insider's "30 Under 40 in Healthcare" list.

Farzad Mostashari

Aledade

Aledade's CEO and founder, Farzad Mostashari, was included in the Washingtonian's list of the 500 most influential people of 2023.

Ed Park

Devoted Health

Devoted Health's CEO and co-founder, Ed Park, was named in Boston Globe's 2023 "Tech Power Player" list.

10x Genomics was included in Fast Company's “Top 10 Most Innovative Biotech Companies” list.

Fast Company

Aledade saved Medicare more than $572 million in a year, returning $177 million to the taxpayer.

Aledade

Apogee Therapeutics broke the biotech IPO dry spell and closed an upsized IPO.

BioSpace

Carmot Therapeutics entered into a definitive merger agreement with Roche.

Carmot Therapeutics

Devoted Health was awarded Best Place to Work by several publications.

Great Place to Work  |  Fast Company  |  Boston Business Journal

Element Biosciences announced the availability of a $200 genome on their AVITI Benchtop Sequencing System.

Element Biosciences

Included Health expanded its virtual-first primary care to Walmart associates after a multi-year test led to better health outcomes for employees and lower healthcare costs.

Endpoints News

Lyra Health is now the largest fully integrated, evidence-based mental health network.

Lyra Health

MBrace Therapeutics announced the initiation of patient dosing in the Phase 1 clinical trial evaluating investigational antibody-drug conjugate MBRC-101.

Business Wire

Mythic Therapeutics dosed their first patient with their cMET-Targeting ADC for the treatment of non-small cell lung cancer.

Mythic Therapeutics

RayzeBio closed an upsized $358M initial public offering and was acquired by Bristol Myers Squibb for $4.1B.

RayzeBio  |  Barron's

SmithRx announced they will be the first pharmacy benefit manager (PBM) to offer Yusimry, an adalimumab biosimilar, for one-tenth the list price of Humira.

AJMC

Suki AI was included in Fast Company's "Next Big Things In Tech" list.

Fast Company

Virta Health was recognized as one of the TIME100 Most Influential Companies.

TIME

I've been following him since before he was 'cool'. He is an incredibly talented musician, and if his normal sound isn't for you, definitely check out his NPR Tiny Desk performance.

— Kevin Kao

A successful Wall Street trader turned expert high-performance wellness coach. He helps busy corporate professionals rebalance with the tools to become elite in all areas of their life.

— Lesley Kelly

A laugh-out-loud podcast on the latest in tech news — with an emphasis on AI. Kevin Roose and Casey Newton are hilarious and savvy — a great distraction while you exercise or walk the dog — that keeps you current on relevant content.

— Cami Samuels